Sinopep-Allsino Bio to Set Up Joint Venture With Vazyme Biotech

Jiangsu Sinopep-Allsino Biopharmaceutical said it stays competitive despite the US hiking tariffs on Chinese goods, Yicai Global reported April 25, citing investor meeting notes from the Chinese pharmaceutical company.

The company attributed its competitive advantage to the higher gross profit margins of its products and its clients' limited price sensitivity, as well as scarce high-quality production capacity, the report said.

The report said that the company is looking to expand into Russia, South America, and Southeast Asia, among other emerging markets, in order to mitigate the impact of the tariffs.

Jiangsu Sinopep-Allsino Biopharmaceutical said its Lianyungang facility passed China's good manufacturing practice inspection for granule production lines.

The Jiangsu Drug Administration certified the compliance after an onsite review that ended Feb. 20, according to a Friday filing with the Shanghai bourse.

Jiangsu Sinopep-Allsino Biopharmaceutical obtained approval to export tirzepatide as an active pharmaceutical ingredient (API) to the European Union, according to a Thursday filing with the Shanghai Stock Exchange.

Sinopep-Allsino's factory in Lianyungang passed the EU's good manufacturing practice compliance for export, the filing said.

Tirzepatide is indicated for type 2 diabetes.

Nanjing Vazyme Biotech partnered with Shenzhen BGI Genomics to develop genetic products, according to a Shanghai Stock Exchange filing on Saturday.

Both parties signed a five-year agreement to develop reproductive genetics and other genetic projects that will prevent tumors, dementia and other diseases.

The agreement is valid until March 5, 2030, the Chinese biotechnology company said.

Vazyme's shares closed over 2% higher.

Nanjing Vazyme Biotech partnered with Shenzhen BGI Genomics to develop genetic products, according to a Shanghai Stock Exchange filing on Saturday.

Both parties signed a five-year agreement to develop reproductive genetics and other genetic projects that will prevent tumors, dementia and other diseases.

The agreement is valid until March 5, 2030, the Chinese biotechnology company said.

Vazyme's shares closed over 2% higher.

Jiangsu Sinopep-Allsino Biopharmaceutical received good manufacturing practice compliance certifications from South Korea and China's Jiangsu province.

These are semaglutide and fulvestrant active pharmaceutical ingredients (API) for export to South Korea as well as epalrestat and sodium picosulfate APIs for domestic production, according to a Tuesday filing with the Shanghai bourse.

Shares of the biopharmaceutical company were down 3% in recent trade.